- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Wayland Expands Distribution Capabilities Through Agreement with ICC
Wayland Group Corp. (CSE:WAYL; FWB:75M; OTCQB:MRRCF) recently announced a letter of intent (LOI) with International Cannabis Corp. (ICC) (CSE:WRLD.U).
Wayland Group Corp. (CSE:WAYL; FWB:75M; OTCQB:MRRCF) recently announced a letter of intent (LOI) with International Cannabis Corp. (ICC) (CSE:WRLD.U). Under the potential agreement, Wayland Group would sell 49.9 percent of the company’s international asset portfolio and receive 300 million shares of ICC at a price of $0.43 per share, valuing Wayland’s international business at approximately US$258 million.
Under the supply agreement, Wayland Group will supply ICC with 10,000 kilograms of EU-GMP-certified product each year for a total of three years. Wayland Group’s international business will also be held in a subsidiary jointly owned by the two parties.
In a recent interview on MidasLetter Live, Wayland Group CEO Ben Ward discussed the agreement and addressed how it will provide the company with access to a much broader distribution network across Europe.
“Selling half of the business to ICC gets us a broader framework and completes our vertical integration that we’ve been seeking across all the aspects in the value chain,” he said. “So we now have a EU GMP compliant pharmaceutical manufacturing facility in Greece, a federal license in Denmark, which we’ll be developing to give us certainty of product for the EU outside of Canada, and then it also gives us broad distribution.”
In discussing the agreement, Ward also addressed the steps that still need to be taken in order to close the deal. “We’ve already done the due diligence in Greece; we’re impressed with the facilities and the operations there, and we’ll be moving ahead with due diligence in Bulgaria, Denmark, and then in Poland, as well. Those are the places that we have yet to see. Our team was in Colombia last week, so there is really little left to do on the diligence side of things.”
To see the full interview, click here.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.